The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease
Pharmaceuticals · 14.05.2023 · 16 (5) · 748
DOI: 10.3390/ph16050748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 14.05.2023. Verfasst von Sabrina Schnur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University, 66123 Saarbrücken, Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund (ERDF), European Regional Development Fund (EFRE), project “E-bio Barrier”, BMWI ZIM project Greencure.
Abstract (Originalsprache)
Complementary and alternative medicine has the potential to enrich conventional therapy to improve the treatment of various diseases. Patients that suffer from inflammatory bowel disease, which requires a constant need for medication, have to deal with the adverse effects of repeated application. Natural products such as Epigallocatechin-3-gallate (EGCG) possess the potential to improve symptoms of inflammatory diseases. We investigated the efficacy of EGCG on an inflamed co-culture model simulating IBD and compared it to the efficacies of four commonly applied active pharmaceutical ingredients. EGCG (200 µg/mL) strongly stabilized the TEER value of the inflamed epithelial barrier to 165.7 ± 4.6% after 4 h. Moreover, the full barrier integrity was maintained even after 48 h. This corresponds to the immunosuppressant 6-Mercaptopurin and the biological drug Infliximab. The EGCG treatment significantly decreased the release of the pro-inflammatory cytokines IL-6 (to 0%) and IL-8 (to 14.2%), similar to the effect of the corticosteroid Prednisolone. Therefore, EGCG has a high potential to be deployed as complementary medicine in IBD. In future studies, the improvement of EGCG stability is a key factor in increasing the bioavailability in vivo and fully harnessing the health-improving effects of EGCG.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University, 66123 Saarbrücken, Germany.
- Department of Drug Delivery, PharmBioTec Research and Development GmbH, 66123 Saarbrücken, Germany.
- 3RProducts Marius Hittinger, 6640 Blieskastel, Germany.
ORCID-Profile: Sabrina Schnur, Marc Schneider
Förderung
- European Regional Development Fund (ERDF)
- European Regional Development Fund (EFRE), project “E-bio Barrier”
- BMWI ZIM project Greencure
- Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University
Zitieren
APA
Schnur, S., Hans, F., Dehne, A., Osti, J., Schneemann, M. O., Schneider, M., & Hittinger, M. (2023). The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease. Pharmaceuticals, 16(5), 748. https://doi.org/10.3390/ph16050748
Vancouver
Schnur S, Hans F, Dehne A, Osti J, Schneemann MO, Schneider M, et al. The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease. Pharmaceuticals. 2023;16(5):748. doi:10.3390/ph16050748
BibTeX
@article{Schnur2023,
author = {Schnur, Sabrina and Hans, Fabian and Dehne, Annika and Osti, Janina and Schneemann, Malte-Ole and Schneider, Marc and Hittinger, Marius},
title = {The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {5},
pages = {748},
doi = {10.3390/ph16050748}
}
EUVIMED